Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1816

Sort by

Sort Order Select

Journal Articles

Mammalian VPS45 orchestrates trafficking through the endosomal system

Laura Frey, Natalia Ziętara, Marcin Łyszkiewicz, Benjamin Marquardt, Yoko Mizoguchi, Monika I. Linder, Yanshan Liu, Florian Giesert, Wolfgang Wurst, Maik Dahlhoff, Marlon R. Schneider, Eckhard Wolf, Raz Somech, Christoph Klein

Blood (2021) 137 (14): 1932–1944.

https://doi.org/10.1182/blood.2020006871

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

To be, or not to be

Alessandro Maria Vannucchi

Blood (2020) 135 (19): 1617–1618.

https://doi.org/10.1182/blood.2020005363

Published: 2020

Journal Articles

Verruconis gallopava in a patient with myelofibrosis on ruxolitinib

Andrew Hsu, Veronica Ulici

Blood (2020) 135 (14): 1189.

https://doi.org/10.1182/blood.2020004799

Published: 2020

Journal Articles

Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation

Samuel A. Stoner, Ming Yan, Katherine Tin Heng Liu, Kei-Ichiro Arimoto, Takahiro Shima, Huan-You Wang, Daniel T. Johnson, Rafael Bejar, Catriona Jamieson, Kun-Liang Guan, Dong-Er Zhang

Blood (2019) 134 (20): 1730–1744.

https://doi.org/10.1182/blood.2019000170

Published: 2019

Includes: Supplemental data

Journal Articles

Altered Megakaryocytes Are Associated with Development of Pulmonary Fibrosis in Mice Carrying the Hypomorphic Gata1 low Mutation

Barbara Bacci, PhD, Francesca Gobbo, Mariana Roccaro, Angelo Peli, PhD, Maria Zingariello, PhD, Fabrizio Martelli, PhD, Paola Verachi, Claudio Bardelli, PhD, Maria Mazzarini, Giuseppe Sarli, PhD, Anna Rita Migliaccio, PhD

Blood (2019) 134 (Supplement_1): 2336.

https://doi.org/10.1182/blood-2019-123994

Published: 2019

Journal Articles

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

John Porter, Maria Domenica Cappellini, MD, Thomas Coates, MD, Olivier Hermine, Vip Viprakasit, MD DPhil, Ersi Voskaridou, Hong Keng Liew, Silverio Perrotta, Abderrahim Khelif, Antonis Kattamis, Abderrahmane Laadem, Jeevan K. Shetty, Wen-Ling Kuo, Dimana Miteva, Tatiana Zinger, Peter G. Linde, Daniel Sinsimer, Ali Taher

Blood (2019) 134 (Supplement_1): 2245.

https://doi.org/10.1182/blood-2019-122561

Published: 2019

Journal Articles

TGF-β Signaling Contributes to Myelofibrosis and Clonal Dominance of Myeloproliferative Neoplasms

Juo-Chin Yao, Grazia Abou Ezzi, PhD, Joseph R. Krambs, BS, Salil Uttarwar, Eric J. Duncavage, MD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 470.

https://doi.org/10.1182/blood-2019-128943

Published: 2019

Journal Articles

Megakaryocyte Ablation Ameliorates Bone Marrow Fibrosis By Reducing Myofibroblast Differentiation in a Mouse Model of Primary Myelofibrosis

Yutein Chung, PhD, Huiyan Jin, PhD, Claire Trasorras, Francina Gonzalez, Sang Hee Min, MD PhD

Blood (2019) 134 (Supplement_1): 2493.

https://doi.org/10.1182/blood-2019-132186

Published: 2019

Journal Articles

Direct Comparison of Long-Term Outcome of Allogeneic Transplantation for Myelofibrosis in Chronic and Leukemic Stage in a Single Institute

Shinsuke Takagi, Takashi Mitsuki, MD, Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Daisuke Kaji, MD, Yuki Taya, MD PhD, Aya Nishida, MD, Kazuya Ishiwata, MD, Hisashi Yamamoto, MD PhD, Go Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Naoyuki Uchida, MD PhD, Atsushi Wake, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2019) 134 (Supplement_1): 5382.

https://doi.org/10.1182/blood-2019-129859

Published: 2019

Journal Articles

Overall Survival in Patients with JAK2 and ASXL1 Positive Myeloproliferative Neoplasms

Murtadha Al-Khabori, MD, Shoaib Al-Zadjali, PhD, Iman Al Noumani, Khalil Al Farsi, Salam Al-Kindi, MD, Mohamed Al Huneini, MD, Naglaa Fawaz, MBBChir, MMSc, PhD, Al Lamki Sulayma, MD, Mahdiya Pir Al Bulushi, MD FRCPC, Khalid Al Hashmi, MD, Muna Al Tarshi, MD, Muhanna Almusalhi

Blood (2019) 134 (Supplement_1): 5383.

https://doi.org/10.1182/blood-2019-128309

Published: 2019

Journal Articles

Genetic and Clinical Features of Chronic Myelmonocytic Leukemia with Fibrosis

Mohammad O Hussaini, MD, Jinming Song, MD PhD, Andrew T Kuykendall, MD, David A Sallman, MD, Eric Padron, MD, Rami S. Komrokji, MD, Sayeef Mirza, MDMPH, Ling Zhang, MD

Blood (2019) 134 (Supplement_1): 5442.

https://doi.org/10.1182/blood-2019-128997

Published: 2019

Journal Articles

Efficacy Analysis of Ruxolitinib in Treatment of 72 Patients with Myelofibrosis in a Chinese Institution

Yunfan Yang, MD, Zhongqing Zou, MD, Ting Liu, MD PhD, Yongqian Jia, PhD, Ting Niu, MD PhD, Huanling Zhu, MD, Yu Wu, MD, Yuping Gong, MD, Hong Chang, MD, Jie Ji, MD, Jian Li, MD, Ling Pan

Blood (2019) 134 (Supplement_1): 5384.

https://doi.org/10.1182/blood-2019-128553

Published: 2019

Journal Articles

The Grey Zone: Characterization of Aggressive High-Grade B-Cell Malignancy with TdT Expression and IGH/BCL2 and MYC Rearrangement

Shonali Midha, MD, Julio C. Chavez, MD, Hayder Saeed, MD, Celeste Bello, MD, Farhad Khimani, MD, Silvia Tse Bunting, MD MSc, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 5347.

https://doi.org/10.1182/blood-2019-130721

Published: 2019

Journal Articles

Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

Claire N Harrison, Professor, Aaron T. Gerds, MD MS, Jean-Jacques Kiladjian, MD PhD, Konstanze Döhner, Sarah A Buckley, MD, Jennifer A. Smith, PhD, Adam R Craig, MD PhD, John Mascarenhas, MD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 4175.

https://doi.org/10.1182/blood-2019-129245

Published: 2019

Journal Articles

Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms

Blood (2019) 134 (Supplement_1): 4238.

https://doi.org/10.1182/blood-2019-126967

Published: 2019

Journal Articles

Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies

Ruben A. Mesa, MD, Moshe Talpaz, MD, Jean-Jacques Kiladjian, MD PhD, Claire N Harrison, Professor, Srdan Verstovsek, MD PhD, Sarah A Buckley, MD, Karisse Roman-Torres, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 4195.

https://doi.org/10.1182/blood-2019-124129

Published: 2019

Journal Articles

Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis

Naveen Pemmaraju, MD, Krishna Gundabolu, MBBS, Kristen Pettit, MD, Moshe Talpaz, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Peter Eisenberg, MD, Hagop Youssoufian, MD, Susan Duggan, RN, MBA, Barbara Wallner, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 4178.

https://doi.org/10.1182/blood-2019-130310

Published: 2019

Journal Articles

Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients

Claire N Harrison, Professor, Andrea Patriarca, MD, John Mascarenhas, MD, Marina Kremyanskaya, Ronald Hoffman, MD, Gary J. Schiller, MD, Brian Leber, MD, Timothy Devos, MD PhD, Sujan Kabir, MD, Adrian Senderowicz, MD, Jennifer Mertz, PhD, Patrick Trojer, PhD, James Shao, MS, Vikas Gupta, MD FRCP, FRCPath

Blood (2019) 134 (Supplement_1): 4164.

https://doi.org/10.1182/blood-2019-128211

Published: 2019

Journal Articles

Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Guillermo Garcia-Manero, MD, Ghulam J. Mufti, Pierre Fenaux, MD PhD, Rena Buckstein, MD FRCPC, Valeria Santini, MD, María Díez-Campelo, MD PhD, Carlo Finelli, Mario Cazzola, MD, Osman Ilhan, Mikkael A. Sekeres, MD MS, Alan F. List, MD, Abderrahmane Laadem, Rodrigo Ito, Jennie Zhang, Anita Rampersad, Daniel Sinsimer, Peter G. Linde, Uwe Platzbecker, MD, Rami Komrokji

Blood (2019) 134 (Supplement_1): 4243.

https://doi.org/10.1182/blood-2019-123048

Published: 2019

Journal Articles

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Eric Jourdan, MD, Richard T. Silver, MD, Harry C Schouten, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Juan Shen, PhD, Tymara Berry, MD, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 4165.

https://doi.org/10.1182/blood-2019-130069

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Mammalian VPS45 orchestrates trafficking through the endosomal system

To be, or not to be

Verruconis gallopava in a patient with myelofibrosis on ruxolitinib

Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation

Altered Megakaryocytes Are Associated with Development of Pulmonary Fibrosis in Mice Carrying the Hypomorphic Gata1 low Mutation

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

TGF-β Signaling Contributes to Myelofibrosis and Clonal Dominance of Myeloproliferative Neoplasms

Megakaryocyte Ablation Ameliorates Bone Marrow Fibrosis By Reducing Myofibroblast Differentiation in a Mouse Model of Primary Myelofibrosis

Direct Comparison of Long-Term Outcome of Allogeneic Transplantation for Myelofibrosis in Chronic and Leukemic Stage in a Single Institute

Overall Survival in Patients with JAK2 and ASXL1 Positive Myeloproliferative Neoplasms

Genetic and Clinical Features of Chronic Myelmonocytic Leukemia with Fibrosis

Efficacy Analysis of Ruxolitinib in Treatment of 72 Patients with Myelofibrosis in a Chinese Institution

The Grey Zone: Characterization of Aggressive High-Grade B-Cell Malignancy with TdT Expression and IGH/BCL2 and MYC Rearrangement

Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms

Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies

Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis

Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only